Trimetazidine Attenuates Heart Failure by Improving Myocardial Metabolism via AMPK

Trimetazidine Attenuates Heart Failure by Improving Myocardial Metabolism via AMPK

Energic deficiency of cardiomyocytes is a dominant cause of heart failure. An antianginal agent, trimetazidine improves the myocardial energetic supply. We presumed that trimetazidine protects the cardiomyocytes from the pressure overload-induced heart failure through improving the myocardial metabo...

Full description

Bibliographic Details
Main Authors: Hongyang Shu, Weijian Hang, Yizhong Peng, Jiali Nie, Lujin Wu, Wenjun Zhang, Dao Wen Wang, Ning Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Pharmacology
Subjects:
pressure overload
heart failure
myocardial metabolism
AMPK
trimetazidine
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.707399/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.707399/full

Similar Items